259 related articles for article (PubMed ID: 36253408)
1. CSF GAP-43 as a biomarker of synaptic dysfunction is associated with tau pathology in Alzheimer's disease.
Qiang Q; Skudder-Hill L; Toyota T; Wei W; Adachi H
Sci Rep; 2022 Oct; 12(1):17392. PubMed ID: 36253408
[TBL] [Abstract][Full Text] [Related]
2. The Trajectory of Cerebrospinal Fluid Growth-Associated Protein 43 in the Alzheimer's Disease Continuum: A Longitudinal Study.
Zhang H; Lyu D; Jia J;
J Alzheimers Dis; 2022; 85(4):1441-1452. PubMed ID: 34958042
[TBL] [Abstract][Full Text] [Related]
3. CSF 14-3-3 zeta(ζ) isoform is associated with tau pathology and cognitive decline in Alzheimer's disease.
Qiang Q; Skudder-Hill L; Toyota T; Huang Z; Wei W; Adachi H;
J Neurol Sci; 2024 Feb; 457():122861. PubMed ID: 38194803
[TBL] [Abstract][Full Text] [Related]
4. Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study.
Vrillon A; Mouton-Liger F; Martinet M; Cognat E; Hourregue C; Dumurgier J; Bouaziz-Amar E; Brinkmalm A; Blennow K; Zetterberg H; Hugon J; Paquet C
Alzheimers Res Ther; 2022 May; 14(1):71. PubMed ID: 35606871
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
Shaw LM; Vanderstichele H; Knapik-Czajka M; Clark CM; Aisen PS; Petersen RC; Blennow K; Soares H; Simon A; Lewczuk P; Dean R; Siemers E; Potter W; Lee VM; Trojanowski JQ;
Ann Neurol; 2009 Apr; 65(4):403-13. PubMed ID: 19296504
[TBL] [Abstract][Full Text] [Related]
6. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
8. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
9. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
[TBL] [Abstract][Full Text] [Related]
10. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
11. Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals.
Öhrfelt A; Benedet AL; Ashton NJ; Kvartsberg H; Vandijck M; Weiner MW; Trojanowski JQ; Shaw LM; Zetterberg H; Blennow K;
Neurology; 2023 Jan; 100(3):e275-e285. PubMed ID: 36192174
[TBL] [Abstract][Full Text] [Related]
12. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid growth-associated protein 43 levels in patients with progressive and stable mild cognitive impairment.
Lu Y;
Aging Clin Exp Res; 2022 Oct; 34(10):2399-2406. PubMed ID: 35988117
[TBL] [Abstract][Full Text] [Related]
14. Peripheral Markers of Vascular Endothelial Dysfunction Show Independent but Additive Relationships with Brain-Based Biomarkers in Association with Functional Impairment in Alzheimer's Disease.
Drake JD; Chambers AB; Ott BR; Daiello LA;
J Alzheimers Dis; 2021; 80(4):1553-1565. PubMed ID: 33720880
[TBL] [Abstract][Full Text] [Related]
15. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
[TBL] [Abstract][Full Text] [Related]
16. Association between CSF Aβ42 and amyloid negativity in patients with different stage mild cognitive impairment.
He B; Wang L; Xu B; Zhang Y;
Neurosci Lett; 2021 May; 754():135765. PubMed ID: 33667602
[TBL] [Abstract][Full Text] [Related]
17. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.
Shaw LM; Vanderstichele H; Knapik-Czajka M; Figurski M; Coart E; Blennow K; Soares H; Simon AJ; Lewczuk P; Dean RA; Siemers E; Potter W; Lee VM; Trojanowski JQ;
Acta Neuropathol; 2011 May; 121(5):597-609. PubMed ID: 21311900
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
20. Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment.
Babić Leko M; Borovečki F; Dejanović N; Hof PR; Šimić G
J Alzheimers Dis; 2016; 50(3):765-78. PubMed ID: 26836160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
